Delisting and clinical outcomes of liver transplant candidates after hepatitis C virus eradication: A long-term single-center experience - 11/11/21
, Dzhamal T. Abdurakhmanov a, Teona P. Rozina a, b, Elena N. Nikulkina a, Elena L. Tanaschuk a, Sergey V. Moiseev a, bBienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
| pages | 9 |
| Iconographies | 3 |
| Vidéos | 0 |
| Autres | 0 |
Highlights |
• | Successful antiviral therapy leads to delisting of above 50% cirrhotic patients. |
• | Male gender, baseline class C, prothrombin index dynamics are non-delisting factors. |
• | HCC risk is lower in delisted patients, but is not eliminated completely. |
Abstract |
Background |
Previous short-term studies have reported on liver function improvements and delisting among liver transplantation (LT) candidates with hepatitis C virus (HCV) and decompensated liver cirrhosis after successful antiviral therapy. This study aimed to evaluate the long–term impact of HCV eradication on liver function, portal hypertension, probability of delisting, and clinical outcomes in patients awaiting LT.
Methods |
Forty-five LT candidates with decompensated HCV cirrhosis were prospectively observed after HCV eradication by direct-acting antiviral therapy. The median follow-up (FU) time was 24 months.
Results |
Twenty-six (57.8%) patients were delisted due to clinical improvement. Multivariate analysis revealed male gender (hazard ratio (HR) 3.28; p = 0.022), baseline Child – Turcotte – Pugh class C (HR 4.81; p = 0.003), and delta prothrombin index <2% between baseline and the time of sustained virological response (HR 3.82; p = 0.01) as independent risk factors for non-delisting. During a median FU of 21 months after delisting, hepatocellular carcinoma (HCC) developed in 2 (7.7%) patients. Among non-delisted patients, HCC developed in 6 (31.6%) cases, variceal bleeding developed in 3 (15.8%) patients, and spontaneous bacterial peritonitis developed in 2 (10.5%) patients.
Conclusion |
HCV eradication lead to the delisting of more than 50% of patients, but did not eliminate the HCC risk, and close monitoring of patients should continue after the end of treatment.
Le texte complet de cet article est disponible en PDF.Keywords : Hepatitis C, Liver cirrhosis, Waiting list, Direct-Acting antivirals
Plan
Vol 45 - N° 6
Article 101714- novembre 2021 Retour au numéro
Article précédent
- Assessment of Lactobacillus casei rhamnosus (LGG) therapy in children with biliary atresia – Randomized placebo controlled trial
- Ewa Orłowska, Piotr Czubkowski, Katarzyna Wołochowska, Dorota Jarzębicka, Ilona Motyl, Piotr Socha
- Neonatal cholestasis and Niemann-pick type C disease: A literature review
- L. López de Frutos, J.J. Cebolla, I. de Castro-Orós, P. Irún, P. Giraldo
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’achat d’article à l’unité est indisponible à l’heure actuelle.
Déjà abonné à cette revue ?